Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has put out new guidance numbers that would see the company hit revenue numbers never seen before. Saviuk telling Proactive the new guidance is suggesting the company could see its fourth quarter of 2022 go to 12.5-13 million with is ahead of previous guidance that was set at 11 million. Fiscal 2022 guidance has also increased to 27.5-28 million which is well ahead of 2021. The driver behind the increase is the success of its asthma therapies and the low molecular weight heparin biosimilar REDESCA.
Valeo Pharma announces revenue guidance has been raised to a record 12.5 to 13 million in Q4
